{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T09:14:53Z","timestamp":1771146893759,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T00:00:00Z","timestamp":1447977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"RAS-LR7\/2007","award":["CRP-24879"],"award-info":[{"award-number":["CRP-24879"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Recent studies have suggested a possible role of high levels of plasma lysophosphocholines (lyso<jats:styled-content style=\"fixed-case\">PC<\/jats:styled-content>s) in fibromyalgia syndrome (<jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content>). The aim of this study was to evaluate the content of plasma phospholipases (e.g., Platelet Activating Factor Acetyl Hydrolase [<jats:styled-content style=\"fixed-case\">PAF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">AH<\/jats:styled-content>], secretory Phospholipase A<jats:sub>2<\/jats:sub> [<jats:styled-content style=\"fixed-case\">sPLA<\/jats:styled-content><jats:sub>2<\/jats:sub>], Total Antioxidant Capacity [<jats:styled-content style=\"fixed-case\">TAOC<\/jats:styled-content>] and 2,7,8\u2010trimethyl\u20102\u2010(2\u2010carboxyethyl)\u20106\u2010hydroxy chroman [\u03b3\u2010<jats:styled-content style=\"fixed-case\">CEHC<\/jats:styled-content>]) in <jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content> patients and their association with clinical status and quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Thirty\u2010six females meeting the 2011 American College of Rheumatology criteria for the classification of <jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content> and thirty\u2010four healthy females were enrolled for the study. Plasma enzyme levels were quantified using commercial enzyme\u2010linked\u2010immunosorbent\u2010assay (<jats:styled-content style=\"fixed-case\">ELISA<\/jats:styled-content>). In order to assess the disease severity and the functional status of patients, the Fibromyalgia Impact Questionnarie (<jats:styled-content style=\"fixed-case\">FIQ<\/jats:styled-content>) was used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Higher levels of <jats:styled-content style=\"fixed-case\">sPLA<\/jats:styled-content><jats:sub>2<\/jats:sub> and lower <jats:styled-content style=\"fixed-case\">PAF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">AH<\/jats:styled-content> and \u03b3\u2010<jats:styled-content style=\"fixed-case\">CEHC<\/jats:styled-content> were observed in the plasma of <jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content> patients compared to the controls. A decrease in <jats:styled-content style=\"fixed-case\">PAF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">AH<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">TAOC<\/jats:styled-content> levels were found in severe <jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content> (S\u2010<jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content>) compared to mild\/slight (<jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content>) forms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results of the study indicate a possible involvement of phospholipases and \u03b3\u2010<jats:styled-content style=\"fixed-case\">CEHC<\/jats:styled-content> in fibromyalgia syndrome.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.12787","type":"journal-article","created":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T11:46:19Z","timestamp":1448019979000},"page":"550-554","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Plasma phospholipase, \u03b3\u2010<scp>CEHC<\/scp> and antioxidant capacity in fibromyalgia"],"prefix":"10.1111","volume":"20","author":[{"given":"Antonella","family":"Fais","sequence":"first","affiliation":[{"name":"Department of Life and Environmental Sciences University of Cagliari Monserrato Cagliari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Cacace","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences \u201cMario Aresu\u201d University of Cagliari Monserrato Cagliari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Atzori","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences University of Cagliari Monserrato Cagliari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Era","sequence":"additional","affiliation":[{"name":"Department of Life and Environmental Sciences University of Cagliari Monserrato Cagliari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences \u201cMario Aresu\u201d University of Cagliari Monserrato Cagliari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,11,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/CBF.S38161"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2013.818657"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2012.08.028"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2014-0086"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2013.5260"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107626"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0507292"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1016\/S0021-9258(18)89023-8","article-title":"Substrate Specificity of Plasma Lysolecithin Acyltransferase and the Molecular Species of Lecithin Formed by the Reaction","volume":"260","author":"Subbaiah PV","year":"1985","journal-title":"J Biol Chem"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2006.05.008"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2009.06.007"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.7"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-1981(99)00158-4"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2006.06.017"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-13-105"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.1548"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1300\/J094v05n04_02"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2014.03.035"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2004.12.001"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20140"},{"key":"e_1_2_8_22_1","first-page":"S154","article-title":"The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses","volume":"23","author":"Bennett R","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"e_1_2_8_23_1","first-page":"227","article-title":"Fibromialgia:qualit\u00e0 di vita e sindromi associate","volume":"58","author":"Cacace E","year":"2006","journal-title":"Reumatismo"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-5-17"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R045492"},{"key":"e_1_2_8_26_1","first-page":"S121","article-title":"Is fibromyalgia\u2010related oxidative stress implicated in the decline of physical and menthal health status?","volume":"31","author":"Rubia M","year":"2013","journal-title":"Clin Exper Rheumatol"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12787","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T06:15:33Z","timestamp":1695536133000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,20]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1111\/1756-185X.12787"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12787","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,20]]},"assertion":[{"value":"2015-11-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}